Saturday, October 31, 2026

15:30 - 17:00

Lecture Theatre 5

---

Details

Traditional pharmacovigilance systems are increasingly challenged by the speed, scale and complexity of modern vaccine deployment, with timely evidence generation and public confidence critical during both routine immunisation programmes and public health emergencies. Emerging approaches that integrate population data, digital epidemiology, AI-enabled intelligence and collaborative global surveillance networks are redefining how vaccine safety signals can be detected, investigated and interpreted in near real time. Our expert team will lead a journey through practical delivery of next-gen real-world evidence in the context of ever-increasing demand for rapid, transparent and responsive vaccine pharmacovigilance. Why real-world evidence matters in vaccine pharmacovigilance: Hazel Clothier — Experienced vaccine safety epidemiologist leading vaccine vigilance programs across Australia and multinational collaborations — will introduce how traditional pharmacovigilance approaches are increasingly challenged by the complexity of modern vaccine deployment, and why integrated real-world evidence approaches are needed to reshape contemporary vaccine vigilance. 1. Vaccine safety signal investigation in practice: An end-to-end case study: Daneeta Hennessy — Operational vaccine safety investigator with expertise translating emerging safety signals into evidence-based public health assessment and communication — will provide a practical walkthrough of an end-to-end vaccine safety investigation, demonstrating how a potential safety concern was identified, assessed and interpreted through the integration of complementary surveillance systems and epidemiological methods. 2. The highs & lows of using large-linked data systems: John Mallard — Early career researcher with practical expertise in large, linked data analyses for vaccine safety evaluation — will demonstrate how population-wide linked datasets enable powerful post-licensure vaccine safety analyses and investigations following new vaccine introductions, while also highlighting the practical challenges and considerations required when using real-world linked-data for surveillance. 3. From community concern to evidence: The role of primary care data: Aishwarya Shetty — Emerging pharmacoepidemiologist specialising in use of primary healthcare datasets — will examine the growing role of primary care data in vaccine pharmacovigilance, using a case study to highlight how these data can sometimes be the only source able to answer emerging safety concerns, capture syndromic surveillance patterns, and strengthen transparent, evidence-based responses to community concerns. 4. AI-enabled infodemic surveillance and vaccine safety intelligence: Gerardo Luis Dimaguila — Health informatician and AI researcher— will show how AI pipeline approaches monitoring online media vaccine sentiment can strengthen infodemic management, supporting earlier detection of emerging safety concerns, mis/disinformation signals, and shifts in vaccine confidence, while generating actionable intelligence for communication, surveillance and response. 5. Advancing vaccine vigilance in Indonesia: Jarir At Thobari — Pharmacology Professor and vaccinologist at Universitas Gadjah Mada, Indonesia — will discuss how AI-enabled surveillance can support responses to recent vaccine confidence challenges in Indonesia, highlighting the value of locally engaged partnerships in designing vaccine vigilance systems that are responsive to regional needs. 6. Global collaborative vaccine vigilance and the 100 days mission: Jim Buttery — Global leader in collaborative vaccine pharmacovigilance and multinational real-world evidence generation — will conclude the symposium with a forward-looking discussion on multinational vaccine vigilance frameworks and how federated real-world evidence approaches across globally connected surveillance networks, including low- and middle-income countries, can support rapid vaccine safety evaluation, accelerated evidence generation and pandemic preparedness goals aligned with CEPI’s 100 Days Mission. To examine how emerging real-world evidence approaches are enabling faster, more connected and more scalable vaccine pharmacovigilance, providing practical insight into how innovative data sources, methods, and collaborative surveillance frameworks can strengthen rapid evidence generation, public confidence and preparedness for future vaccine rollout challenges and public health emergencies. This symposium highlights contemporary pharmacoepidemiology approaches using real-world evidence to strengthen vaccine safety surveillance and rapid evidence generation. This is particularly relevant across the Asian region where expanding immunisation programs, growing digital health capability and advancement in collaborative surveillance models are accelerating innovation in vaccine pharmacovigilance.

---

Speaker